Life Sciences Archive » September, 2006

Life Sciences - September, 2006

118 articles

• Law Firm Profile: Merchant & Gould
• Baxter Gets Surprise Setback In Japanese Ultane Ruling
• Report: FDA Should Improve Defibrillator Communication
• Barr Launches Generic Actiq
• Jury Deadlocks In Wyeth Hormone Replacement Trial
• Sanofi-Aventis Scores Trademark Victory
• King & Spalding Lures In IP Prosecution Team
• SeraCare Shareholders Denied Bid To Slow Proceedings
• Lawsuit Over High-Tech Braces Settled With $20M Deal
• European Court Sides With Glaxo In Dual Pricing Case
• Encysive Pharmaceuticals Hit With Securities Suit
• Barr Challenges Savient's Oxandrin Patents
• Merck Scores Second Win In Vioxx Onslaught
• Hospital Stole Trade Secrets, Biotech Firm Charges
• J&J Sues Abbott, Boston Scientific For Over $5.5B
• Federal Circuit Upholds Dietary Supplement Rulings
• EU Regulator To Re-Examine Safety Of Common Drugs
• Drug Makers Toss Authorized Generic Plan
• As Vioxx Deadline Looms, Merck Faces More Suits
• Novartis' Indian Patent Challenge Could Harm: MSF
• Schwarzenegger Kills Universal Health Care Bill
• Merck Lawyers Can Dig Through Juror's Personal Records
• FDA Plans Studies Of On-The-Market Medications
• Study Finds FDA Falling Short of Drug Safety Expectations
• New Jersey Hospitals Present Unique Outlier Cases
• Guidant Sues St. Jude Over Salespeople Recruitment
• Cytyc Reaffirms Offer For Vision Systems
• Merck Appeals $26M Jury Verdict In First Vioxx Case
• Appeals Court Upholds Dismissal Of Enzo Fraud Claim
• Doctors Bring Class Action Against Health Insurers
• Congress Pens Deal To Allow Canada Drug Imports
• Male Enhancement Maker Charged With Fraud
• Federal Circuit Rules In Scantibodies' Favor
• SeraCare Modifies Chapter 11 Plan Amid Rival Bids
• Judge Rules For Sanofi, Bristol-Myers In Plavix Case
• Senate Battle Lies Ahead For FDA Nominee
• Connetics Hit With Shareholder Lawsuit Over Failed Drug
• GlaxoSmithKline Royalties Come Under Scrutiny
• Datasci Settles Patent Litigation Against Datalabs
• Forest Executives Win Battle Against Shareholders
• AMS Health Sciences Settles Ephedra Suit
• Fueled By IP, U.S. Still Biotech Leader: Study
• Corporate America More Gay Friendly: Study
• Takeda Wins Attorneys Fees In Patent Suit
• Appeals Court Vacates Securities Class Action Decision
• Pfizer Not Happy With Former Executive's Book
• Messy Health Care Merger To End Up In Court
• Enzo Settles DNA Patent Dispute
• Antitrust Fears Raised Over Potential Rite Aid Merger
• Judge Orders ImClone's Scientists Off Patent
• 2nd Van Der Moolen Trader Acquitted Of Front-Running
• In Win For Barr, Court Denies Tamoxifen Rehearing
• Wyeth Wins First Hormone Replacement Therapy Case
• Clotting Data Prompts FDA To Promise Stent Review
• Execs Sentenced For Marketing Unapproved Devices
• Bristol-Myers Begs Court To Preserve Plavix Injunction
• Guidant Buries One Hatchet In Defibrillator Fallout
• Baker Donelson Nabs White House Bigwig
• Australia Bids To Bolster Generic Drug Industry
• Concessions Mark Solvay Settlement
• Battle Between Medical Device Makers Continues
• FDA Panel Shoots Down Oscient Request
• Acambis Says Willing To Settle In Patent Fight
• Mixed Victory For Pfizer In Dutch Lipitor Battle
• Biopure Escapes Damages In SEC Suit, GC Doesn't
• Cadwalader Nabs Morgan Lewis Antitrust Partner
• FDA Whistleblower Blasts New Merck Painkiller
• Bristol-Myers Head Fired Amid Plavix Debacle
• Jury Mulls Evidence In Wyeth Premarin Trial
• The Impact Of Laboratory Corp. V. Metabolite On The Question Of Patentable Subject Matter
• SeraCare Loses Control Of Its Chapter 11 Case
• Cross Country Healthcare Settles California Wage Suit
• Judge Bounces Derivative Suit Against Cell Therapeutics
• Companies Battle Over Bone Cleaning Technology
• Stryker Plays Down DOJ Probe
• Amgen's Preemptive Strike Survives Motion To Dismiss
• Amid Slump In Federal Litigation, Some Buck Trend
• SEC Hits Valeant With Multi-Pronged Probe
• Whistleblower Case v. Pfizer Dismissed
• Pharmacists' Suit Over Morning-After Pill To Proceed
• FDA Advisors Question Mercury Fillings Report
• DOJ Joins Whistleblower Suit Against Merck Affiliate
• Scrutiny Of Deals Jumped In 2005: FTC Report
• FDA Concerned With Side Effect of Oscient Drug
• Jury Hands Innogenetics $7M In Damages
• Glaxo Agrees To $3.4B Settlement
• Pfizer Faces New Personal-Injury Suits Over Lipitor
• Law Firm's Investigation Finds Merck Innocent
• DEA Wants To Change Rules For Schedule II Drugs
• PTO Strikes Down Ariad's Patent
• Barr Tries To Cut Generic Market By Entering It
• Medical Method Patents
• Acambis Gets Boost With Smallpox Vaccine Ruling
• Fulbright Raids Sonnenschein To Expand Health Care Group
• Apotex Appeals Plavix Injunction To Federal Circuit
• Trial Date Set For NatWest Three
• Howrey Adds Three Experts To Brussels Office
• Medtronic Settles With Gyrus In Financial Draw
• J&J To Cough Up Millions More In Patent Case
• California Governor Will Nix Health Care Bill
• Novartis Sues To Protect Market For Epilepsy Drug
• GlaxoSmithKline Scores Parallel Trade Victory
• Biotech Companies Settle Animal Cloning Patent Suit
• Federal Circuit Hits J&J Unit With One-Two Punch
• Roche Wants New Ruling On Tarceva
• Abbott Defeated In HCV Patent Feud
• Hunton & Williams Acquires L.A. Trial Boutique
• Judge Denies Apotex Bid For Stay On Injunction
• Biotech Companies Settle Secretive Patent Suit
• FDA Hits Snooze Button on Neurocrine's Sleep Drug
• Class Action Against Pharmaceutical Co. Dismissed
• Judge Refuses To Review Amgen Case
• Fish & Richardson Ranked #1 In Patent Litigation
• Compounded Medicines Legal, Federal Judge Rules
• Court Grants Injunction Barring Generic Plavix
• FDA Rejects Sanofi-Aventis Drug Application
• Arnold & Porter Ranked #1 In Antitrust Litigation
• Pfizer Wins Another Battle In Norvasc War